Modality
ASO
MOA
CGRPant
Target
CD38
Pathway
NF-κB
CeliacGastric Ca
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
Aug 2020
→ Apr 2026
Phase 1Current
NCT05275202
742 pts·Celiac
2023-06→TBD·Recruiting
NCT08559699
2,677 pts·Gastric Ca
2020-08→2026-04·Not yet recruiting
3,419 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-01tomorrowPh2 Data· Gastric Ca
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Not yet…
P1/2
Recruit…
Catalysts
Ph2 Data
2026-04-01 · tomorrow
Gastric Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05275202 | Phase 1/2 | Celiac | Recruiting | 742 | VA |
| NCT08559699 | Phase 1/2 | Gastric Ca | Not yet recr... | 2677 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 |